Managing Editor of the Journal of Thoracic Oncology | Tweets are my own | Bluesky handle: bsky.app/profile/vslim.bsky.…

Asia Pacific
#WCLC25 It takes a village! Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @IASLC! @DrAlexAdjei @JTOonline @ElsevierConnect #JTO #JTOCRR
12
835
Vun-Sin Lim, PhD retweeted
🧵1 Antibody-drug conjugates (ADCs) are transforming the treatment of lung cancer, but pulmonary toxicity remains an important clinical concern. Our systematic review & meta-analysis @JTOonline evaluated pulmonary AEs assoc with ADCs in SCLC and NSCLC @Rparedes_MD @OSUCCC_James
2
15
36
1,371
Vun-Sin Lim, PhD retweeted
JTO20 Marks 20 Years of Progress in Thoracic Oncology - Vun-Sin Lim @vs_lim oncodaily.com/societies/vun-…
1
2
272
Sneak Peek🎙️1st in-person recording of JTO Insights at #WCLC26! Ep. 12 guest: @ReckampK Hosts: @DrAlexAdjei @TommyJohn00 Podcast team: Laura Woodruff & Kelsey Reed 📆 Episode release: Sep 24 🔗 Podcast homepage: jto.org/content/jto-insights 📜 #JTO article: jto.org/article/S1556-0864(2…
2
9
243
Vun-Sin Lim, PhD retweeted
Celebrating a leader who has helped support scientific discovery and knowledge sharing for three years. Thank you, Carolyn Dresler. #JTO20
1
2
319
It's been a privilege to be a part of the @JTOonline team and to gather for the #JTO20 milestone at #WCLC26 ➡️ @IASLC Awards Luncheon: past & present editors + managing editors ➡️ Editors not in attendance were recognized as well during the luncheon ➡️ JTO editorial board mtg
2
3
28
1,570
Special thanks to my editorial team Bailey Creamer and Amiee DeSouza for the incredible support in the JTO 20th celebration and the JTO editorial office, respectively. Grateful for the unwavering support from the @IASLC and @ElsevierConnect in making this happen!
63
Vun-Sin Lim, PhD retweeted
🔥Genomic & transcriptomic features of relapsed SCLC 🆙 @JTOonline 🎯MYC/MYCL/MYCN amplifications; immune evasion via CD24 amp, IDO1 overexpression & HLA-E upregulation; splicing aberrations in relapse 🎙Dr. Siddhartha Devarakonda & Dr. Ramaswamy Govindan #LCSM @OncoAlert @Larvol jto.org/article/S1556-0864(2…
8
18
1,924
Vun-Sin Lim, PhD retweeted
🔥Final biomarker & efficacy analyses of lorlatinib in ALK+ advanced NSCLC — Phase 2 🆙 @JTOonline 🎯EML4::ALK variant 3 (ctDNA): shorter OS in EXP2-3A 🎯TP53 mutation associated with shorter OS in all cohorts 🎯No acquired ALK mutations in treatment-naïve 🎯Substantial activity & prolonged OS maintained across subgroups 🎙Dr. Todd Bauer @BenjaminBesseMD @EnriquetaFelip @DRCamidge @bensolomon1 #LCSM @OncoAlert @Larvol @ALKPositiveinc
8
21
1,730
#WCLC26 Meet the Editors-in-Chief of #JTO @DrAlexAdjei and #JTOCRR Emily Stone Thanks to those who stopped by and engaged in a great conversation or were simply there to listen and learn from the editors. @IASLC @JTOonline @ElsevierConnect
3
15
864
Vun-Sin Lim, PhD retweeted
Thanks @HHorinouchi! 5 years of work, a PhD and some white hair later, delighted to share our work in @JTOonline. We show multi-omic profiling enables molecular risk stratification of stage I-III EGFRm NSCLC to inform adjuvant TKI benefit. Grateful to my mentors and co-authors 🙏🏻
🔥Multi-omic profiling enables recurrence risk stratification beyond pathological stage in resected EGFR-mutant LUAD 🆙 @JTOonline ☑Genomic instability, TP53 co-mutations & transcriptomic features profiled 🎯Multi-omic model C-index 75.4% across 4 validation cohorts 🎯High vs Low Risk in Stage I: IA HR 12.53, IB HR 18.10 🎯Benefit by Adjuvant TKI: Low Risk➖ High Risk➕ 🎙 @stephanieplsaw @danieltanmd #LCSM @OncoAlert @Larvol @EGFRResisters jto.org/article/S1556-0864(2…
2
7
39
4,167
Vun-Sin Lim, PhD retweeted
Featured during #WCLC26 🚨: ADAURA, a global phase III adjuvant trial in EGFR-mutated stage IB-IIIA NSCLC, saw the longest overall survival in any trial of its kind. These landmark results only further characterize the established survival benefit of adjuvant osimertinib. Read now: jto.org/article/S1556-0864(2…
7
11
1,060
🔥Simultaneous JTO publication🔥
🔥ADAURA: Adjuvant osimertinib — exploratory 8-year OS landmark update #WCLC2026 🆙 @JTOonline 🎯8-y OS 74% (osimertinib) vs 58% (placebo; HR 0.53); IB-IIIA: 79% vs 64% (HR 0.52) 🎯Ex19del shows stronger OS benefit (HR 0.45) vs L858R (HR 0.72) 🎯Llongest OS follow-up in adjuvant EGFR NSCLC trial 🎙Dr. Yi-Long Wu @ThomasW35874311 @DrRoyHerbst #LCSM @OncoAlert @Larvol @EGFRResisters jto.org/article/S1556-0864(2…
1
2
11
744
Vun-Sin Lim, PhD retweeted
8 year update of ADAURA at #WCLC26 from @DrRoyHerbst - with 3y of adjuvant osimertinib in EGFR mutant NSCLC, 8y OS rate 74% vs 58% with OS HR 0.53 and benefit seen across stages: stage IB HR 0.50, stage II HR 0.60, stage IIIA HR 0.49 - reaffirms standard of care.
1
45
95
4,007
Vun-Sin Lim, PhD retweeted
Great to meet the @IASLC @JTOonline managing editor @vs_lim in person at the JTO lounge!! Peep her new @TheCORGILab sticker! Hoping for @TheCORGILab’s first publication in @JTOonline soon 🙏🏼
4
12
398
Vun-Sin Lim, PhD retweeted
Meet the Editors at #WCLC26! 📚 JTO Editor-in-Chief Dr. Alex Adjei and JTO Clinical and Research Reports Editor-in-Chief Dr. Emily Stone are meeting with attendees and sharing insights on publishing, research and the IASLC journals. Great conversation happening now!
5
18
1,092
Wondering about reasons papers get rejected, what papers are good fit for JTO and JTO CRR etc? Have a chat or just listen to the conversations with our Editors-in-Chief on Sunday. @DrAlexAdjei @JTOonline @IASLC #WCLC26 #JTO #JTOCRR #JTO20
2
10
358
Vun-Sin Lim, PhD retweeted
🎊Science Without Boudaries🌏🌎🌍 🔥#AI Powered Real-Time Captioning and Translation 🌟It really works🤖 #LCSM @IASLC @OncoAlert @Larvol
🌟 #WCLC26 🆕 Features 🗣️Enjoy in YOUR Language 🇰🇷🇨🇳🇺🇸🇯🇵🇪🇸🇫🇷🇮🇹🇩🇪... 🔥 #AI Powered Real-Time Captioning and Translation 🎯Available for all conference sessions 🔗More to learn: wclc.iaslc.org/onsite-inform… #LCSM @IASLC @OncoAlert
4
9
2,918
Vun-Sin Lim, PhD retweeted
#WCLC26 Awards luncheon begins with a recognition of @JTOonline 20th anniversary! Congrats to the past and current editors🎉
7
26
1,241